A new study reveals how Artemisia annua unique molecule artemisinin and its derivatives are able not only to treat parasitic disorders but also to balance the immune system that directly benefits the host.Details
The newspaper interviews our CEO of Biotech Tricopharming Research Luis Matias, who explains how our Artennua product works and what growth and development prospects we expect. Luis also focuses on the strategic importance of Canary Islands for Artennua production. Indeed, Artennua could become an important crop for the region given its valuable and international trade…Details
Biotech Tricopharming Research wins its first Fyde CajaCanarias Emprendedores 2019 award.
Today, on World Entrepreneur Day, we received an amazing news: we are winners of the 23th Canary Islands Entrepreneurship Award by FYDE. The CajaCanaria Bank Foundation supporting the entrepreneurship (Fundación Canaria para la Formación y Desarrollo Empresarial de CajaCanarias) selected the finalists from different islands. The jury was composed by the General Director of the…Details
Artennua and Tricopharming selected as finalist in the Canary Islands Entrepreneur Award by FYDE Caja Canaria, 23th edition
Tricopharming as been selected as finalist company in the Canary Islands Entrepreneurship Award by Fyde CajaCanarias. Tomorrow our CEO Luis Matías Hernández will give its pitch about Artennua, first Tricopharming product. Artennua is produced in our ecologic farm El Pico in Tejina, Tenerife Island. The project started in Tenerife in 2017 thanks to CDTI funding and…Details
Innovation and agriculture, medicinal plants and biotechnology, this is Tricopharming. Using biological techniques we stimulate the natural capacity of the plants trichomes to be molecules factory. A well done article titled “Biopharmaceutical Agriculture, from the laboratory to the field”, Newspaper La Vanguardia tells our story: our company, our first product and our plans for the…Details
Pharmaceutical agriculture, from the laboratory to the field
Sequentia Biotech creates the spin-out Biotech Tricopharming Research to market Artennua, its first biopharmaceutical agriculture product.